References
Simon T, Langler A, Harnischmacher U, Fruhwald MC, Jorch N, Claviez A et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol 2007; 133: 653–661.
Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B . Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011; 56: 578–583.
Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013; 31: 599–607.
Robinson BW, Cheung NK, Kolaris CP, Jhanwar SC, Choi JK, Osheroff N et al. Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood 2008; 111: 3802–3812.
Pegram LD, Megonigal MD, Lange BJ, Nowell PC, Rowley JD, Rappaport EF et al. t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (guanosine 5' monophosphate synthetase) gene. Blood 2000; 96: 4360–4362.
Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA 2000; 97: 2814–2819.
Meyer C, Schneider B, Reichel M, Angermueller S, Strehl S, Schnittger S et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005; 102: 449–454.
Lykke-Andersen J . Identification of a human decapping complex associated with hUpf proteins in nonsense-mediated decay. Mol Cell Biol 2002; 22: 8114–8121.
Bai RY, Koester C, Ouyang T, Hahn SA, Hammerschmidt M, Peschel C et al. SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. Nat Cell Biol 2002; 4: 181–190.
Strehl S, Borkhardt A, Slany R, Fuchs UE, Konig M, Haas OA . The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21). Oncogene 2003; 22: 157–160.
Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD et al. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 2003; 22: 8448–8459.
Krumbholz M, Jung R, Bradtke J, Reinhardt D, Stachel D, Metzler M . Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene. Leuk Lymphoma 2015 56: 793–796.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Krumbholz, M., Bradtke, J., Stachel, D. et al. From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML. Bone Marrow Transplant 50, 1382–1384 (2015). https://doi.org/10.1038/bmt.2015.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.155
- Springer Nature Limited